{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:45:27Z","timestamp":1788299127523,"version":"build-2803163510"},"reference-count":64,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["F.No. 52\/11\/2022-BIO\/BMS; IRIS ID:2021-13086"],"award-info":[{"award-number":["F.No. 52\/11\/2022-BIO\/BMS; IRIS ID:2021-13086"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Dengue viral infection is caused by the Dengue virus, which spreads to humans through the bite of infected mosquitos. Dengue affects over half of the global population, with an estimated 500 million infections per year. Despite this, no effective treatment is currently available, however, several promising candidates are undergoing pre-clinical\/clinical testing. The existence of four major serotypes is an important challenge in the development of drugs and vaccines to combat Dengue virus infection. Hence, the drug\/vaccine thereby developed should neutralize all the four serotypes equally. However, there is no pan-serotype specific treatment for Dengue virus, thereby emphasizing the need for the identification of novel drug-like compounds that can target all serotypes of the Dengue virus equally. To this end, we employed virtual screening methodologies to find drug-like compounds that target the domain III of glycoprotein E. Most importantly, domain III of E protein is involved in viral fusion with the host membrane and is also targeted by neutralizing antibodies. Our study found two small molecule drug-like compounds (out of the 3 million compounds screened) having similar binding affinity with all four serotypes. The compounds thereby identified exhibit favourable drug like properties and can be developed as a treatment for Dengue virus.<\/jats:p>","DOI":"10.1371\/journal.pone.0311548","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T17:38:49Z","timestamp":1729877929000},"page":"e0311548","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Structure-based identification of small-molecule inhibitors that target the DIII domain of the Dengue virus glycoprotein E pan-serotypically"],"prefix":"10.1371","volume":"19","author":[{"given":"Prakhar","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant","family":"Arya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3122-4475","authenticated-orcid":true,"given":"Ganesan","family":"Senthil Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"key":"pone.0311548.ref001","unstructured":"Dengue- Global situation. [cited 10 Mar 2024]. Available: https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2023-DON498."},{"key":"pone.0311548.ref002","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00284-020-02284-w","article-title":"Current Understanding of the Pathogenesis of Dengue Virus Infection","volume":"78","author":"P Bhatt","year":"2021","journal-title":"Curr Microbiol"},{"key":"pone.0311548.ref003","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40506-023-00263-w","article-title":"Dengue: Update on Clinically Relevant Therapeutic Strategies and Vaccines","volume":"15","author":"M Palanichamy Kala","year":"2023","journal-title":"Curr Treat Options Infect Dis"},{"key":"pone.0311548.ref004","doi-asserted-by":"crossref","first-page":"e0006209","DOI":"10.1371\/journal.pntd.0006209","article-title":"Neutralization of antibody-enhanced Dengue virus infection by VIS513, a pan-serotype reactive monoclonal antibody targeting domain III of the Dengue virus E protein","volume":"12","author":"Y Budigi","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"pone.0311548.ref005","article-title":"A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Determine the Safety and Pharmacokinetics of AV-1 in Healthy Male and Female Adult Subjects","author":"LLC AbViro","year":"2022","journal-title":"clinicaltrials.gov"},{"key":"pone.0311548.ref006","unstructured":"Serum Institute of India Pvt. Ltd. A Phase I, Partially Blind (Observer-blind), Randomized, Single Dose Ascending Study of Dengue Monoclonal Antibody (Dengushield) in Healthy Adults. clinicaltrials.gov; 2020 Feb. Report No.: NCT03883620. Available: https:\/\/clinicaltrials.gov\/study\/NCT03883620."},{"key":"pone.0311548.ref007","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent Dengue virus vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"MR Capeding","year":"2014","journal-title":"Lancet Lond Engl"},{"key":"pone.0311548.ref008","doi-asserted-by":"crossref","first-page":"5614","DOI":"10.1016\/j.vaccine.2023.07.045","article-title":"A Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a tetravalent live attenuated Dengue virus vaccine in adults","volume":"41","author":"B Gunale","year":"2023","journal-title":"Vaccine"},{"key":"pone.0311548.ref009","doi-asserted-by":"crossref","first-page":"102598","DOI":"10.1016\/j.tmaid.2023.102598","article-title":"Qdenga\u00ae - A promising Dengue virus fever vaccine; can it be recommended to non-immune travelers?","volume":"54","author":"M Angelin","year":"2023","journal-title":"Travel Med Infect Dis"},{"key":"pone.0311548.ref010","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1016\/S1473-3099(22)00311-5","article-title":"Monoclonal antibody therapies against SARS-CoV-2","volume":"22","author":"D Focosi","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"pone.0311548.ref011","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41577-019-0123-x","article-title":"Adaptive immune responses to primary and secondary Dengue virus infections","volume":"19","author":"AL St John","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"pone.0311548.ref012","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.chom.2007.03.002","article-title":"The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection","volume":"1","author":"TC Pierson","year":"2007","journal-title":"Cell Host Microbe"},{"key":"pone.0311548.ref013","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41586-021-03990-6","article-title":"A pan-serotype Dengue virus inhibitor targeting the NS3-NS4B interaction","volume":"598","author":"SJF Kaptein","year":"2021","journal-title":"Nature"},{"key":"pone.0311548.ref014","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.antiviral.2013.06.002","article-title":"Nuclear localization of Dengue virus (Dengue virus) 1\u20134 non-structural protein 5; protection against all 4 Dengue virus serotypes by the inhibitor Ivermectin","volume":"99","author":"MYF Tay","year":"2013","journal-title":"Antiviral Res"},{"key":"pone.0311548.ref015","doi-asserted-by":"crossref","first-page":"e0098821","DOI":"10.1128\/AAC.00988-21","article-title":"Evaluation of AT-752, a Double Prodrug of a Guanosine Nucleotide Analog with In Vitro and In Vivo Activity against Dengue and Other Flaviviruses","volume":"65","author":"SS Good","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0311548.ref016","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00705-013-1880-7","article-title":"Inhibitory effect of doxycycline against Dengue virus replication in vitro","volume":"159","author":"HA Rothan","year":"2014","journal-title":"Arch Virol"},{"key":"pone.0311548.ref017","doi-asserted-by":"crossref","first-page":"e586","DOI":"10.1093\/cid\/ciaa1332","article-title":"Ivermectin Accelerates Circulating Nonstructural Protein 1 (NS1) Clearance in Adult Dengue Patients: A Combined Phase 2\/3 Randomized Double-blinded Placebo Controlled Trial","volume":"72","author":"Y Suputtamongkol","year":"2021","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"pone.0311548.ref018","unstructured":"Atea Pharmaceuticals, Inc. A Phase 1, Double-blind, Randomized, Placebo-controlled Study to Assess the Antiviral Activity and Safety of AT-752 in a Dengue Human Challenge Model. clinicaltrials.gov; 2023 Apr. Report No.: NCT05366439. Available: https:\/\/clinicaltrials.gov\/study\/NCT05366439."},{"key":"pone.0311548.ref019","unstructured":"Atea Pharmaceuticals, Inc. A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of AT-752 in Patients With Dengue Infection. clinicaltrials.gov; 2024 Feb. Report No.: NCT05466240. Available: https:\/\/clinicaltrials.gov\/study\/NCT05466240."},{"key":"pone.0311548.ref020","unstructured":"Janssen Research & Development, LLC. A Phase 2, Randomized, Double-blind, Placebo-controlled, Double-dummy, Multicenter Trial Assessing the Efficacy and Safety of Two Dose Regimens of JNJ-64281802 for the Prevention of Dengue Infection. clinicaltrials.gov; 2024 Feb. Report No.: NCT05201794. Available: https:\/\/clinicaltrials.gov\/study\/NCT05201794."},{"key":"pone.0311548.ref021","unstructured":"Janssen Research & Development, LLC. A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Antiviral Activity, Safety and Tolerability, and Pharmacokinetics of JNJ-64281802 in Participants With Confirmed Dengue Fever. clinicaltrials.gov; 2024 Feb. Report No.: NCT04906980. Available: https:\/\/clinicaltrials.gov\/study\/NCT04906980."},{"key":"pone.0311548.ref022","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2174\/1574891X10666150410153839","article-title":"Dengue Patients Treated with Doxycycline Showed Lower Mortality Associated to a Reduction in IL-6 and TNF Levels","volume":"10","author":"TM Fredeking","year":"2015","journal-title":"Recent Patents Anti-Infect Drug Disc"},{"key":"pone.0311548.ref023","doi-asserted-by":"crossref","first-page":"e2188","DOI":"10.1371\/journal.pntd.0002188","article-title":"Sulfated Polysaccharide, Curdlan Sulfate, Efficiently Prevents Entry\/Fusion and Restricts Antibody-Dependent Enhancement of Dengue Virus Infection In Vitro: A Possible Candidate for Clinical Application","volume":"7","author":"K Ichiyama","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"pone.0311548.ref024","doi-asserted-by":"crossref","first-page":"e428","DOI":"10.1371\/journal.pone.0000428","article-title":"Combinatorial Computational Approaches to Identify Tetracycline Derivatives as Flavivirus Inhibitors","volume":"2","author":"J-M Yang","year":"2007","journal-title":"PLOS ONE"},{"key":"pone.0311548.ref025","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.bbrc.2008.08.100","article-title":"Structure and anti-Dengue virus activity of sulfated polysaccharide from a marine alga","volume":"376","author":"KIPJ Hidari","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"pone.0311548.ref026","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1128\/JVI.02841-13","article-title":"Activation of Peripheral Blood Mononuclear Cells by Dengue Virus Infection Depotentiates Balapiravir","volume":"88","author":"Y-L Chen","year":"2014","journal-title":"J Virol"},{"key":"pone.0311548.ref027","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.bbrc.2014.09.113","article-title":"Suramin inhibits helicase activity of NS3 protein of Dengue virus in a fluorescence-based high throughput assay format","volume":"453","author":"C Basavannacharya","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"pone.0311548.ref028","doi-asserted-by":"crossref","first-page":"e3196","DOI":"10.1002\/psc.3196","article-title":"Carnosine exhibits significant antiviral activity against Dengue and Zika virus","volume":"25","author":"HA Rothan","year":"2019","journal-title":"J Pept Sci"},{"key":"pone.0311548.ref029","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/aps.2015.56","article-title":"Policresulen, a novel NS2B\/NS3 protease inhibitor, effectively inhibits the replication of Dengue virus 2 virus in BHK-21 cells","volume":"36","author":"D Wu","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"pone.0311548.ref030","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.1128\/JVI.00632-13","article-title":"The Small Molecules AZD0530 and Dasatinib Inhibit Dengue Virus RNA Replication via Fyn Kinase","volume":"87","author":"M de Wispelaere","year":"2013","journal-title":"J Virol"},{"key":"pone.0311548.ref031","doi-asserted-by":"crossref","first-page":"14682","DOI":"10.1073\/pnas.1508095112","article-title":"Virion-associated phosphatidylethanolamine promotes TIM1-mediated infection by Ebola, Dengue virus, and West Nile viruses","volume":"112","author":"AS Richard","year":"2015","journal-title":"Proc Natl Acad Sci"},{"key":"pone.0311548.ref032","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.antiviral.2017.03.026","article-title":"Luteolin restricts Dengue virus replication through inhibition of the proprotein convertase furin","volume":"143","author":"M Peng","year":"2017","journal-title":"Antiviral Res"},{"key":"pone.0311548.ref033","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.chembiol.2016.03.010","article-title":"GNF-2 inhibits Dengue virus by targeting Abl kinases and the viral E protein","volume":"23","author":"MJ Clark","year":"2016","journal-title":"Cell Chem Biol"},{"key":"pone.0311548.ref034","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3390\/tropicalmed6040180","article-title":"Current Trends and Limitations in Dengue Antiviral Research","volume":"6","author":"JO Obi","year":"2021","journal-title":"Trop Med Infect Dis"},{"key":"pone.0311548.ref035","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.antiviral.2018.12.016","article-title":"Dengue drug discovery: Progress, challenges and outlook","volume":"163","author":"SP Lim","year":"2019","journal-title":"Antiviral Res"},{"key":"pone.0311548.ref036","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3390\/v15030705","article-title":"Molecular Mechanisms of Antiviral Agents against Dengue Virus","volume":"15","author":"MF Lee","year":"2023","journal-title":"Viruses"},{"key":"pone.0311548.ref037","doi-asserted-by":"crossref","first-page":"5622","DOI":"10.1021\/acs.jmedchem.5b01653","article-title":"The Medicinal Chemistry of Dengue Virus","volume":"59","author":"MAM Behnam","year":"2016","journal-title":"J Med Chem"},{"key":"pone.0311548.ref038","doi-asserted-by":"crossref","first-page":"7769","DOI":"10.1128\/JVI.75.16.7769-7773.2001","article-title":"Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells","volume":"75","author":"WD Crill","year":"2001","journal-title":"J Virol"},{"key":"pone.0311548.ref039","doi-asserted-by":"crossref","first-page":"e0139741","DOI":"10.1371\/journal.pone.0139741","article-title":"Characterization of a Novel Dengue Serotype 4 Virus-Specific Neutralizing Epitope on the Envelope Protein Domain III","volume":"10","author":"G-H Ji","year":"2015","journal-title":"PLoS ONE"},{"key":"pone.0311548.ref040","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1016\/j.vaccine.2006.01.036","article-title":"A recombinant fusion protein containing the domain III of the Dengue virus -2 envelope protein is immunogenic and protective in nonhuman primates","volume":"24","author":"L Hermida","year":"2006","journal-title":"Vaccine"},{"key":"pone.0311548.ref041","doi-asserted-by":"crossref","first-page":"1200195","DOI":"10.3389\/fimmu.2023.1200195","article-title":"Dengue virus neutralizing antibody: a review of targets, cross-reactivity, and antibody-dependent enhancement","volume":"14","author":"A Sarker","year":"2023","journal-title":"Front Immunol"},{"key":"pone.0311548.ref042","doi-asserted-by":"crossref","first-page":"e52384","DOI":"10.7554\/eLife.52384","article-title":"Broadly neutralizing human antibodies against Dengue virus identified by single B cell transcriptomics","volume":"8","author":"ND Durham","journal-title":"eLife"},{"key":"pone.0311548.ref043","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"GM Sastry","year":"2013","journal-title":"J Comput Aided Mol Des"},{"key":"pone.0311548.ref044","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra Precision Glide:\u2009 Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein\u2212Ligand Complexes","volume":"49","author":"RA Friesner","year":"2006","journal-title":"J Med Chem"},{"key":"pone.0311548.ref045","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1021\/jm060522a","article-title":"Accurate Prediction of the Relative Potencies of Members of a Series of Kinase Inhibitors Using Molecular Docking and MM-GBSA Scoring","volume":"49","author":"PD Lyne","year":"2006","journal-title":"J Med Chem"},{"key":"pone.0311548.ref046","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/jcc.20291","article-title":"GROMACS: Fast, flexible, and free","volume":"26","author":"D Van Der Spoel","year":"2005","journal-title":"J Comput Chem"},{"key":"pone.0311548.ref047","article-title":"Water in Biology, Chemistry, and Physics: Experimental Overviews and Computational Methodologies","author":"GW Robinson","year":"1996","journal-title":"World Scientific"},{"key":"pone.0311548.ref048","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/978-94-015-7658-1_21","volume-title":"Intermolecular Forces: Proceedings of the Fourteenth Jerusalem Symposium on Quantum Chemistry and Biochemistry Held in Jerusalem, Israel, April 13\u201316, 1981","author":"HJC Berendsen","year":"1981"},{"key":"pone.0311548.ref049","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/prot.21123","article-title":"Comparison of multiple Amber force fields and development of improved protein backbone parameters","volume":"65","author":"V Hornak","year":"2006","journal-title":"Proteins"},{"key":"pone.0311548.ref050","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/978-1-4613-1571-1_7","volume-title":"Prediction of Protein Structure and the Principles of Protein Conformation","author":"DHJ Mackay","year":"1989"},{"key":"pone.0311548.ref051","first-page":"305037","article-title":"Free energy calculations of protein-water complexes with Gromacs","author":"MA Shahzad","year":"2018","journal-title":"bioRxiv"},{"key":"pone.0311548.ref052","doi-asserted-by":"crossref","first-page":"014101","DOI":"10.1063\/1.2408420","article-title":"Canonical sampling through velocity rescaling","volume":"126","author":"G Bussi","year":"2007","journal-title":"J Chem Phys"},{"key":"pone.0311548.ref053","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/jcc.21773","article-title":"Optimization of parameters for molecular dynamics simulation using smooth particle-mesh Ewald in GROMACS 4.5","volume":"32","author":"MJ Abraham","year":"2011","journal-title":"J Comput Chem"},{"key":"pone.0311548.ref054","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1021\/ct700200b","article-title":"P-LINCS:\u2009 A Parallel Linear Constraint Solver for Molecular Simulation","volume":"4","author":"B. Hess","year":"2008","journal-title":"J Chem Theory Comput"},{"key":"pone.0311548.ref055","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1007\/s00253-018-8822-y","article-title":"Dengue viruses and promising envelope protein domain III-based vaccines","volume":"102","author":"H Fahimi","year":"2018","journal-title":"Appl Microbiol Biotechnol"},{"key":"pone.0311548.ref056","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/ijms19010054","article-title":"Development of Antibody Therapeutics against Flaviviruses","volume":"19","author":"H Sun","year":"2017","journal-title":"Int J Mol Sci"},{"key":"pone.0311548.ref057","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1128\/JVI.01087-10","article-title":"Structure and Function Analysis of Therapeutic Monoclonal Antibodies against Dengue Virus Type 2","volume":"84","author":"S Sukupolvi-Petty","year":"2010","journal-title":"J Virol"},{"key":"pone.0311548.ref058","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0168-1656(99)00037-1","article-title":"A recombinant Fab neutralizes Dengue virus in vitro","volume":"69","author":"P Thullier","year":"1999","journal-title":"J Biotechnol"},{"key":"pone.0311548.ref059","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1099\/0022-1317-82-8-1885","article-title":"Mapping of a Dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism","volume":"82","author":"P Thullier","year":"2001","journal-title":"J Gen Virol"},{"key":"pone.0311548.ref060","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2174\/157340911795677602","article-title":"Molecular Docking: A powerful approach for structure-based drug discovery","volume":"7","author":"X-Y Meng","year":"2011","journal-title":"Curr Comput Aided Drug Des"},{"key":"pone.0311548.ref061","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41570-022-00451-0","article-title":"Rules were made to be broken","volume":"7","author":"IV Hartung","year":"2023","journal-title":"Nat Rev Chem"},{"key":"pone.0311548.ref062","first-page":"1","article-title":"Description and In silico ADME Studies of US-FDA Approved Drugs or Drugs Under Clinical Trial which Violate the Lipinski\u2019s Rule of 5","volume":"20","author":"N Lohit","journal-title":"Lett Drug Des Discov"},{"key":"pone.0311548.ref063","doi-asserted-by":"crossref","first-page":"106774","DOI":"10.1016\/j.phrs.2023.106774","article-title":"Rule of five violations among the FDA-approved small molecule protein kinase inhibitors","volume":"191","author":"R. Roskoski","year":"2023","journal-title":"Pharmacol Res"},{"key":"pone.0311548.ref064","unstructured":"Wrestling with Lipinski\u2019s rule of 5. In: Chemical & Engineering News [Internet]. [cited 12 Mar 2024]. Available: https:\/\/cen.acs.org\/pharmaceuticals\/drug-discovery\/Wrestling-Lipinski-rule-5\/101\/i8."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0311548","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T17:39:07Z","timestamp":1729877947000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0311548"}},"subtitle":[],"editor":[{"given":"Qiang Shawn","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":64,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0311548","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]}}}